- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT02046031
Preliminary Study of Pharmacokinetics of Ginkgolides Meglumine Injection.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Ginkgolides Meglumine Injection was jointly developed by China Pharmaceutical University and Jiangsu Kanion Pharmaceutical Co., Ltd. Its pharmacal ingredients are ginkgo lactones A , ginkgo lactone B, ginkgo lactone K, etc; Excipients for meglumine, citric acid, sodium chloride. It is used to treat stroke (mild-to-moderate cerebral infarction) in recovery phlegm and Syndrome of Intermingled Phlegm and Blood Stasis.
The aim of this study is to explore the rule of absorption, distribution, metabolism and elimination after intravenous administration of Ginkgolides Meglumine Injection healthy subjects. The plasma drug profiles will be important to assess the potential clinical drug-drug interactions.
Biological sample including blood and urine for PK is collected during the study. In the first stage, the biological sample of two subjects will be collected at different time points. In the second stage, the biological sample of another two subjects will be collected at the time points which are adjusted according to the results of the first stage.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 4
Contatti e Sedi
Luoghi di studio
-
-
Jiangsu
-
Nanjing, Jiangsu, Cina, 201129
- The First Affiliated Hospital with Nanjing Medical University
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Ages 18-40, no more than 10 years apart.
- Both male and female.
- Subjects have standard weight( generally not less than 50 kg), and body mass index (BMI) within 19-25. Subjects weight (kg) should not differ too much.
All physical examinations( including ECG, kidney function, liver function
, blood routine, urine routines, etc) are normal.
- History of disease: no history of diseases in gastrointestinal tract, reproductive tract, urinary tract, heart, liver, kidney, lung, nervous system, metabolism, and no history of allergies and orthostatic hypotension.
- After being told all possible adverse reactions associated with the drug, subjects sign the informed consent and promise to complete all examinations.
Exclusion Criteria:
- Subjects who cannot communicate with medical staff, and subjects with cerebral insufficiency or psychological problem.
- Female subjects or partner of male subjects have plan to pregnant.
- Subjects have primary disease in significant organ.
- Subjects have history of drug dependence or psychosis in last 2 years.
- Subjects have blood loss or blood donation more than 200 mL 3 months prior to the baseline.
- Subjects who have taken part in other clinical trials 3 months prior to the baseline.
- Subjects who abuse alcohol or other drugs.
- Pregnancy or breast-feeding subjects.
- Subjects is found to have clinical significance of abnormal after checking information and physical examinations.
- Known allergies or serious side effects with no more than two kinds of food and drugs in the past.
- Subjects who have taken any drug during the previous 2 weeks.
- Subjects have unexplained infections.
- The subjects could not complete the study in the opinion of the Principal Investigator due to any reason.
- Positive HIV、HCV and HBsAg test results.
- A female subject whose pregnancy test is positive.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: Ginkgolides Meglumine Injection
Intravenous drip slowly.
A 1 (25 mg), will be taken slowly into the 0.9% sodium chloride injection diluted in 250 ml before use, then slow intravenous drip, once a day.
The dripping speed must be strictly controlled.
For the first time when using Ginkgolides Meglumine Injection, dripping speed should be controlled for 10 ~ 15 drops per minute.
After 30 minutes treatment without discomfort, dripping speed can be appropriately increased, but no more than 30 drops per minute.
|
25 mg, ivdrip, once.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Maximum plasma concentration (Cmax)
Lasso di tempo: 0, 4 days.
|
Blood will be drawn from adult subjects pre-drug application and at 30min, 60min, 90min, 150min, 197min, 205min, 215min, 240min (4h), 300min(5h), 360min (6h), 480min (8h), 720min (12h),1440min(24h),2160min(36h), 2880min (48h), 4320min (72h).
Urine will be drawn from adult subjects pre-drug application and at 0-4, 4-6, 6-12, 12-24, 24-48, 48-72.
|
0, 4 days.
|
Time to maximum plasma concentration (Tmax)
Lasso di tempo: 0, 4 days.
|
Biological sample including blood, urine, faeces for PK will be collected at the same time point.
|
0, 4 days.
|
Area under the curve (AUC)
Lasso di tempo: 0, 4 days.
|
Biological sample including blood, urine, faeces for PK will be collected at the same time point.
|
0, 4 days.
|
Elimination half-life (t1/2)
Lasso di tempo: 0, 4 days.
|
Biological sample including blood, urine, faeces for PK will be collected at the same time point.
|
0, 4 days.
|
clearance (CL)
Lasso di tempo: 0, 4 days.
|
Biological sample including blood, urine, faeces for PK will be collected at the same time point.
|
0, 4 days.
|
Volume of distribution (Vd)
Lasso di tempo: 0, 4 days.
|
Biological sample including blood, urine, faeces for PK will be collected at the same time point.
|
0, 4 days.
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Safety assessments will be based on adverse event reports and the results of vital sign measurements, electrocardiogram, Electrocardiogram monitoring and clinical laboratory tests.
Lasso di tempo: 0, 4days
|
Adverse event reports will be assessed at 0, 4 days.
Vital sign measurements will be assessed at pre-drug application and 30min, 60mi, 120min, 197min, 4h, 12h, 24h, 48h, 72h after application.
Electrocardiogram will be assessed at 0, 4 days.
Electrocardiogram monitoring will be assessed during medication period.
Clinical laboratory tests will be assessed at 0, 4 days.
|
0, 4days
|
Collaboratori e investigatori
Collaboratori
Investigatori
- Investigatore principale: Ou Ning, The First Affiliated Hospital with Nanjing Medical University
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- Z-YXPU-ZS-IV3
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Ginkgolides Meglumine Injection
-
Jiangsu Kanion Pharmaceutical Co., LtdBeijing Bionovo Medicine Development Co., Ltd.Completato
-
Jiangsu Kanion Pharmaceutical Co., LtdBeijing Bionovo Medicine Development Co., Ltd.Completato
-
Changhai HospitalNon ancora reclutamentoLinfoma a cellule B recidivato o refrattario
-
Ruijin HospitalReclutamentoLinfoma a cellule B recidivato o refrattarioCina
-
Shanghai Junshi Bioscience Co., Ltd.CompletatoCarcinoma polmonare non a piccole cellule avanzato naïve al trattamentoCina
-
Bio-Thera SolutionsCompletato
-
Eye & ENT Hospital of Fudan UniversityChanghai Hospital; Shanghai Zhongshan Hospital; Fujian Medical University Union... e altri collaboratoriNon ancora reclutamentoCarcinoma rinofaringeo ricorrenteCina
-
Beijing Biostar Pharmaceuticals Co., Ltd.Reclutamento
-
Hallym University Medical CenterReclutamento
-
SCRI Development Innovations, LLCIpsenTerminatoNeoplasie gastrointestinali | Tumori neuroendocrini | Tumori carcinoidiStati Uniti